The U.S. Food and Drug Administration (FDA) proposed changes that would allow institutional review boards (IRBs) to waive or alter requirements for obtaining informed consent for clinical trials involving minimal risk to participants. Under current FDA regulations, exceptions for obtaining informed consent can only be made in life-threatening situations or when conditions for emergency research are met. (Regulatory Focus)